Depressive disorders are a leading cause of disability in older age. Although the role of psychosocial and behavioural predictors has been well examined, little is known about the biological origins of depression. Findings from animal studies have implicated insulin-like growth factor 1 (IGF-1) in the aetiology of this disorder. A total of 6017 older adults (mean age of 65.7 years; 55% women) from the English Longitudinal Study of Ageing provided serum levels of IGF-1 (mean = 15.9 nmol l⁻¹, s.d. 5.7) during a nurse visit in 2008. Depression symptoms were assessed in the same year and again in 2012 using the eight-item Center for Epidemiologic Studies Depression Scale. Self-reports of a physician-diagnosis of depression were also collected at both time points. In separate analyses for men and women, the results from both the cross-sectional and longitudinal analyses revealed a 'U'-shaped pattern of association, such that lower and higher levels of IGF-1 were associated with a slightly elevated risk of depression, whereas the lowest risk was seen around the median levels. Thus, in men, with the lowest quintile of IGF-1 as the referent, the age-adjusted odds ratios (95% confidence interval) of developing depression symptoms after 4 years of follow-up, for increasing quintiles of IGF-1, were: 0.51 (0.28–0.91), 0.50 (0.27–0.92), 0.63 (0.35–1.15) and 0.63 (0.35–1.13) (P-value for quadratic association 0.002). Some attenuation of these effects was apparent after adjustment for co-morbidity, socioeconomic status and health behaviours. In conclusion, in the present study of older adults, there was some evidence that moderate levels of IGF-1 levels conferred a reduced risk of depression.

Translational Psychiatry (2016) 6, e898; doi:10.1038/tp.2016.167; published online 20 September 2016
Depression symptoms were ascertained during a computer-assisted method. The inter-assay coefficient of variation for IGF-1 across a range of levels was $\leq 3.7\%$, and the intra-assay coefficient of variation was $\leq 5.3\%$. The IGF-1 values are reported as whole numbers (range: 3–200 nmol l$^{-1}$).40

Depressive symptoms and physician-diagnosis of depression
Depression symptoms were ascertained during a computer-assisted personal interview using the eight-item Center for Epidemiologic Studies Depressive (CES-D8) scale.43 Each item requires a dichotomous (yes/no) response, and scores range between 0 and 8 (higher score denotes more severe symptoms). Consistent with other analyses, we defined ‘caseness’ as anyone scoring 4 or above.42 The CES-D has been widely used in population-based studies of older groups43,44 and has been validated against clinician-assessed depression.45 Notably, the shortened CES-D8 has good internal consistency (Cronbach’s $\alpha = 0.78$) and similar psychometric properties to the full 20-item CES-D.46 The participants also had an opportunity to self-report a physician-diagnosis of depression. During the main English Longitudinal Study of Ageing interview, the participants first reported whether they had ever been diagnosed with any emotional, nervous or psychiatric problems. This was followed by the identification of the actual condition as selected from a list of ailments common to this group, of which depression was one.47 The assessment of depression in this manner has been shown to be valid in a separate study using the Structured Clinical Interview for DSM-IV Axis I Disorders as the gold standard.48 Both these measurements of depression were made in 2008 and 2012.

Measurement of covariates
We grouped covariates, including potential confounders and mediators, according to theme. Anthropometric measures comprised height and weight, which were measured during the nurse visit; body mass index (kg/m$^2$) calculated by dividing each individual’s measured weight by height squared. Psychosocial factors were level of education (no qualification, completed secondary (high school) education, educated beyond secondary education but below degree level, and educated beyond degree level); quintiles of net non-pension wealth (derived from an estimation of financial wealth and physical assets reported by study participants and their partners, excluding pension savings and net of debts such as credit cards and loans);49 and marital status (currently living with a partner or not). Health-related behaviours comprised smoking status (current, ex-smoker and never), frequency of alcohol consumption in the past year (less than daily/daily, with consumption on at least 5 days of the week being classed as daily consumption) and leisure time physical activity (low/sedentary, moderate or high activity of exercises such as jogging, cycling, gardening, walking). Co-morbidities were self-reported physician-diagnosis of cancer, diabetes or cardiovascular disease (heart murmur, ischaemic heart disease, abnormal heart rhythm, stroke, valvular heart disease or any other reported heart disease).

Statistical analysis
In Figure 1, we illustrate the flow of participants through the study. Of the 8218 participants at baseline in 2008 who had received a nurse visit, we excluded those who had missing values for IGF-1 ($N = 2158$) comprising people who declined to give blood ($77\%$), unsuitability or loss of a blood sample ($39\%$), or failure to obtain blood sample ($992$). We also excluded participants with missing values for depression symptoms (43), although none had missing data for physician-diagnosed depression at baseline. The cross-sectional sample therefore comprised 6017 study members from data collection in 2008. We also carried out the longitudinal analyses, again using IGF-1 values from 2008 but relating to new (incident) cases of depression at resurvey in 2012. In deriving new cases of depression, we excluded participants who were classed as depression cases in 2008, resulting in samples of 4419 for the analysis of depression symptoms and 4768 for physician-diagnosed depression.

Multivariable logistic regression analyses were used to summarize the association of IGF-1 levels with both depression outcomes. The lowest quintile of IGF-1 was used as the referent. There is existing evidence of differential IGF-1-depression relationships in men and women,39,40,50 so we present gender-specific analyses here also. We adjusted effect estimates for known covariates in a stepwise manner. In our analyses, depression symptoms were our primary outcome, with physician-diagnosed depression used to test convergence of evidence. All the analyses were carried out using Stata12SE software.51

RESULTS
IGF-1 and baseline characteristics: cross-sectional analyses
In Table 1 (women) and Table 2 (men), we present baseline study participant characteristics according to IGF-1 quintiles. As expected, mean IGF-1 values were higher in men (16.5 nmol l$^{-1}$) than women (15.2 nmol l$^{-1}$). In men and women, IGF-1 was inversely associated with age and directly related to height and...
socioeconomic position. Psychosocial factors, which included social position and cohabiting with a partner, typically occurred at more favourable levels in men and women with higher IGF-1 values. A total of 776 participants (12.9%) had CES-D8 scores of 4 and above at baseline and were therefore denoted as ‘cases’ (71.8% were female); 344 (5.7%) participants reported physician-diagnosis of depression. As for some of the somatic conditions such as cancer, there was a suggestion that the greatest proportions of both men and women who reported high depression symptoms and self-declared physician-diagnosed depression were seen at the lowest and highest quintiles of IGF-1, although the differences across groups were not considerable.

**IGF-1 and depression: cross-sectional analyses**

In Table 3, the computation of odds ratios for the cross-sectional association between IGF-1 and depression symptoms supports earlier evidence of a somewhat higher risk of depression symptoms at opposite ends of the IGF-1 continuum in men and women in this study. Although a similar 'U'-shaped pattern was apparent for physician-diagnosed depression (see Supplementary Table 1), statistical significance at conventional levels was rarely apparent for individual point estimates in these analyses. Adjustment for an array of covariates had little impact on this pattern of association, although taking into account all covariates simultaneously led to some flattening of the IGF-1–depression relationship.

**DISCUSSION**

The main finding of this study of older people was that having IGF-1 levels at opposing ends of the continuum was associated with a slightly higher risk of depression symptoms. Similar results were apparent for physician-diagnosis of depression.

Comparison with existing studies

Our results partially accord with the two population studies on IGF-1 and depression of which we are aware. When compared with data from the Study of Health in Pomerania in Germany,\(^{38}\) IGF-1 and depression: prospective analyses

In Table 4, we depict the association between IGF-1 and depression symptoms after 4 years of follow-up in participants initially free of depression symptoms at baseline (longitudinal analyses). A 'U'-shaped pattern of risk was again observed for the IGF-1–depression association in both genders based on symptomatology. Similar results were apparent for physician-diagnosis of depression but only among women (Supplementary Table 2). Statistical significance was, again, rarely apparent for individual point estimates. In none of our analyses was there strong statistical evidence that gender modified the IGF-1–depression association (P-values for interaction for the multiply adjusted odds of developing depression symptoms and physician-diagnosed depression in longitudinal analyses are 0.531 and 0.275, respectively).

---

### Table 1. Baseline characteristics of study participants according to quintiles of serum IGF-1 (nmol l\(^{-1}\)): 3311 women in the English Longitudinal Study of Ageing, 2008

| IGF-1 quintile (range) | Subject numbers | P-value for difference |
|------------------------|-----------------|------------------------|
| (2–11 nmol l\(^{-1}\)) | 861             |                        |
| (12–14 nmol l\(^{-1}\)) | 813             | 0.001                  |
| (15–16 nmol l\(^{-1}\)) | 479             |                        |
| (17–20 nmol l\(^{-1}\)) | 681             | 0.001                  |
| (21–65 nmol l\(^{-1}\)) | 477             |                        |

| IGF-1, nmol l\(^{-1}\), mean (s.e.) | 9.2 (0.06) | 13.0 (0.03) | 15.5 (0.02) | 18.3 (0.04) | 25.2 (0.22) | 15.2 (0.10) | < 0.001 |
| Age, years, mean (s.e.) | 68.7 (0.4) | 66.2 (0.3) | 65.1 (0.4) | 64.4 (0.3) | 63.2 (0.4) | 65.9 (0.2) | < 0.001 |

| Anthropometry mean (s.e.) | Height, cm | 158.8 (0.3) | 159.9 (0.2) | 160.4 (0.3) | 160.6 (0.2) | 160.9 (0.3) | 160.0 (0.1) | < 0.001 |
| BMI, kg/m\(^{2}\) | 28.7 (0.2) | 28.4 (0.2) | 27.6 (0.2) | 27.7 (0.2) | 27.6 (0.2) | 27.6 (0.2) | 28.1 (0.1) | < 0.001 |

| Co-morbidities, % (s.e.) | Diabetes | 8.5 (0.9) | 6.0 (0.8) | 6.9 (1.2) | 5.9 (0.9) | 7.8 (1.2) | 7.0 (0.4) | 0.213 |
| Cancer | 6.6 (0.8) | 4.5 (0.7) | 4.6 (1.0) | 3.2 (0.7) | 6.1 (1.1) | 5.0 (0.4) | 0.029 |
| Cardiovascular disease | 26.6 (1.5) | 24.4 (1.5) | 21.5 (1.9) | 18.6 (1.5) | 23.9 (2.0) | 23.3 (0.7) | 0.005 |

| Psychosocial factors, % (s.e.) | Lowest wealth quintile | 23.1 (1.4) | 16.0 (1.3) | 11.7 (1.5) | 15.0 (1.4) | 14.5 (1.6) | 16.8 (0.7) | < 0.001 |
| No educational qualifications | 34.1 (1.6) | 30.3 (1.6) | 29.0 (2.1) | 27.2 (1.7) | 23.1 (1.9) | 29.4 (0.8) | 0.001 |
| Lives alone | 43.1 (1.7) | 37.5 (1.7) | 28.4 (2.1) | 32.8 (1.8) | 36.3 (2.2) | 36.5 (0.8) | < 0.001 |

| Behavioural factors, % (s.e.) | Sedentary or low physical activity | 39.4 (1.7) | 30.0 (1.6) | 26.5 (2.0) | 25.8 (1.7) | 30.2 (2.1) | 31.1 (0.8) | < 0.001 |
| Current smoking | 12.2 (1.1) | 13.3 (1.2) | 12.7 (1.5) | 13.5 (1.3) | 16.1 (1.7) | 13.4 (0.6) | 0.663 |
| Daily alcohol intake | 15.2 (1.2) | 16.0 (1.3) | 16.5 (1.7) | 15.9 (1.4) | 16.8 (1.7) | 16.0 (0.6) | 0.902 |

| Depression | CES-D score, mean (s.e.) | 1.8 (0.07) | 1.6 (0.07) | 1.3 (0.08) | 1.5 (0.07) | 1.6 (0.09) | 1.6 (0.03) | < 0.001 |
| High depression symptoms, % (s.e.) | 20.6 (1.3) | 15.9 (1.3) | 14.4 (1.6) | 14.2 (1.3) | 17.8 (1.5) | 16.8 (0.7) | 0.005 |
| Physician-diagnosed depression, % (s.e.) | 7.1 (0.9) | 6.4 (0.9) | 5.4 (1.0) | 6.5 (0.9) | 6.7 (1.1) | 6.5 (0.4) | 0.837 |

Abbreviations: BMI, body mass index; CES-D, Center for Epidemiologic Studies Depressive scale; IGF-1, insulin-like growth factor 1.
our results were in agreement with the finding that having a low IGF-1 level was associated with higher risk of developing depression symptoms among women. However, we also found a similar association for men. Our results are also in agreement with the second existing study, which used data from The Longitudinal Aging Study Amsterdam, where associations were found between median levels of IGF-1 and lower risk of both prevalent and incident depression symptoms. Once again, the main difference with this present study is that we identified this association among both men and women. The U-shaped relationship that we identified between IGF-1 and depression symptoms is supported by observations of increased reports of lifetime affective disorders in individuals with lower (pituitary dwarfism) and higher (acromegaly) levels of this growth hormone. It may be that this apparent differential result for men and women in these existing studies is due to statistical instability.

To directly compare our findings with some of those already published, we re-categorized IGF-1 levels in our own analyses. In these new analyses, we still found evidence for increased odds of depression symptoms among those with very low and very high IGF-1. Our results after initial re-categorization of IGF-1 levels showed that, after 4 years of follow-up, the age-adjusted odds ratios (95% confidence interval) of depression symptoms for the lowest and highest tertiles of IGF-1 among men were 1.14 (0.72, 1.80) and 0.89 (0.55, 1.43), respectively, and corresponding results for women were 1.08 (0.79, 1.49) and 1.14 (0.79, 1.65).

Our findings, however, contrast with the results from the handful of case–control studies where IGF-1 levels were found to be elevated in depressed patients compared with healthy controls. This may be owing to specific consequences of previous use of anti-depressant medications, such as where they have been seen to improve expression of IGF-1 and other neurotrophic and growth factors in the hippocampus. Further, there may yet be other unknown biological mechanisms related to the state of being depressed, which cause serum IGF-1 levels to increase, implying reverse causation in the reported case–control studies, where the depression in the cases had, in fact, caused the IGF-1 levels to increase. In this study, we attempted to circumvent the problem of reverse causality by utilizing depression incidence as our outcome in the longitudinal analyses; that is, new cases of depression in participants who, at baseline, were symptom-free and had not previously reported being diagnosed with the condition by a physician.

**Table 2.** Baseline characteristics of study participants according to quintiles of serum IGF-1 (nmol l−1): 2706 men in the English Longitudinal Study of Ageing, 2008

| IGF-1 quintile (range) | 1 | 2 | 3 | 4 | 5 | All | P-value for difference |
|-------------------------|---|---|---|---|---|-----|------------------------|
| (2–11 nmol l−1)         | 483 | 615 | 384 | 667 | 557 |      |                        |
| IGF-1, nmol l−1 (s.e.)  | 9.3 (0.08) | 13.1 (0.03) | 15.5 (0.03) | 18.4 (0.04) | 25.1 (0.22) | 16.5 (0.11) | < 0.001               |
| Age, years, mean (s.e.) | 68.7 (0.5) | 65.3 (0.4) | 65.0 (0.5) | 64.4 (0.3) | 64.0 (0.3) | 65.4 (0.2) | < 0.001               |
| Anthropometry, mean (s.e.) | Height, cm | 171.7 (0.3) | 172.8 (0.3) | 173.8 (0.4) | 173.8 (0.3) | 174.2 (0.3) | 173.3 (0.1) | < 0.001               |
| BMI, kg/m²               | 28.6 (0.2) | 27.8 (0.2) | 27.9 (0.2) | 28.0 (0.2) | 27.9 (0.2) | 28.0 (0.1) | 0.078                 |
| Co-morbidities, % (s.e.) | Diabetes | 12.6 (1.5) | 6.8 (1.0) | 6.3 (1.2) | 10.6 (1.2) | 11.1 (1.3) | 9.6 (5.7) | 0.001               |
| Cancer                  | 4.8 (1.0) | 5.4 (1.0) | 4.4 (1.1) | 5.2 (0.9) | 5.0 (0.9) | 4.3 (0.9) | 4.9 (4.1) | 0.897               |
| Cardiovascular disease  | 31.5 (2.1) | 24.6 (1.7) | 25.7 (2.2) | 26.3 (1.7) | 27.2 (1.9) | 26.9 (0.9) | 0.121               |
| Psychosocial factors, % (s.e.) | Lowest wealth quintile | 18.0 (1.8) | 13.3 (1.4) | 14.3 (1.8) | 12.0 (1.3) | 13.1 (1.4) | 13.9 (0.7) | 0.167               |
| No educational qualifications | 25.9 (2.0) | 20.0 (1.6) | 23.4 (2.1) | 17.3 (1.5) | 16.3 (1.6) | 16.3 (1.0) | 20.1 (0.8) | 0.056               |
| Lives alone             | 26.7 (2.0) | 20.7 (1.6) | 20.8 (2.1) | 21.4 (1.6) | 16.7 (1.6) | 16.7 (1.6) | 21.1 (0.8) | 0.003               |
| Behavioural factors, % (s.e.) | Sedentary or low physical activity | 26.9 (2.0) | 18.4 (1.6) | 22.1 (2.1) | 17.4 (1.5) | 21.9 (1.8) | 20.9 (0.8) | 0.005               |
| Current smoking         | 13.7 (1.6) | 12.7 (1.3) | 12.8 (1.7) | 11.8 (1.3) | 14.0 (1.5) | 12.9 (0.6) | 0.306               |
| Daily alcohol intake    | 28.6 (2.2) | 24.7 (1.7) | 27.6 (2.2) | 26.4 (1.7) | 24.1 (1.8) | 26.1 (0.8) | < 0.001               |
| Depression              | CES-D8 score, mean (s.e.) | 1.0 (0.08) | 0.9 (0.06) | 0.8 (0.07) | 0.9 (0.06) | 1.1 (0.07) | 0.9 (0.03) | 0.07               |
| High depression symptoms, % (s.e.) | 9.3 (1.3) | 7.5 (1.1) | 5.7 (1.0) | 6.7 (1.0) | 11.0 (1.3) | 8.1 (0.5) | 0.018               |
| Physician-diagnosed depression, % (s.e.) | 5.2 (1.0) | 4.2 (0.8) | 4.2 (1.0) | 3.9 (0.7) | 6.5 (1.0) | 4.8 (0.4) | 0.238               |

Abbreviations: BMI, body mass index; CES-D, Center for Epidemiologic Studies Depressive scale; IGF-1, insulin-like growth factor 1.
### Table 3. Odds ratio (95% confidence interval) for the cross-sectional association between serum IGF-1 and depression symptoms: the English Longitudinal Study of Ageing, 2008

| IGF-1 quintile (range) | P-value for linearity | P-value for quadratic |
|------------------------|-----------------------|-----------------------|
| (2–11)                 | (12–14) | (15–16) | (17–20) | (21–65) |
| Women (analytical sample) | | | | |
| Adjustments | | | | |
| Age (3311) | 1 (ref) | 0.76 (0.58, 0.97) | 0.69 (0.50, 0.93) | 0.68 (0.52, 0.90) | 0.91 (0.68, 1.22) | 0.027 | 0.009 |
| Age, anthropometric measures (3181) | 1 | 0.79 (0.61, 1.02) | 0.74 (0.54, 1.01) | 0.72 (0.54, 0.95) | 0.96 (0.71, 1.30) | 0.061 | 0.037 |
| Age, co-morbidities (3308) | 1 | 0.75 (0.58, 0.96) | 0.68 (0.50, 0.92) | 0.69 (0.52, 0.91) | 0.89 (0.66, 1.19) | 0.031 | 0.012 |
| Age, psychosocial factors (3162) | 1 | 0.81 (0.62, 1.06) | 0.79 (0.57, 1.09) | 0.73 (0.55, 0.98) | 0.96 (0.70, 1.30) | 0.494 | 0.26 |
| Age, behavioural factors (2920) | 1 | 0.77 (0.58, 1.02) | 0.76 (0.55, 1.06) | 0.76 (0.56, 1.02) | 0.91 (0.66, 1.25) | 0.08 | 0.078 |
| Multiply adjusted (2691) | 1 | 0.86 (0.63, 1.16) | 0.9 (0.63, 1.29) | 0.85 (0.62, 1.29) | 1 (0.71, 1.41) | 0.756 | 0.199 |
| Men (analytical sample) | | | | |
| Adjustments | | | | |
| Age (2706) | 1 (ref) | 0.75 (0.49, 1.16) | 0.56 (0.33, 0.95) | 0.66 (0.43, 1.02) | 1.12 (0.81, 1.56) | 0.647 | 0.027 |
| Age, anthropometric measures (2627) | 1 | 0.85 (0.54, 1.34) | 0.62 (0.35, 1.02) | 0.79 (0.50, 1.25) | 1.26 (0.81, 1.96) | 0.352 | 0.011 |
| Age, co-morbidities (2696) | 1 | 0.76 (0.49, 1.18) | 0.58 (0.34, 0.98) | 0.64 (0.41, 0.99) | 1.11 (0.73, 1.68) | 0.039 | 0.003 |
| Age, psychosocial factors (2592) | 1 | 0.85 (0.54, 1.34) | 0.61 (0.35, 1.06) | 0.75 (0.47, 1.19) | 1.3 (0.90, 2.16) | 0.015 | 0.045 |
| Age, behavioural factors (2377) | 1 | 0.68 (0.40, 1.16) | 0.57 (0.31, 1.06) | 0.71 (0.43, 1.18) | 1.32 (0.83, 2.12) | <0.001 | 0.052 |
| Multiply adjusted (2277) | 1 | 0.84 (0.47, 1.50) | 0.63 (0.32, 1.24) | 0.84 (0.48, 1.47) | 1.54 (0.90, 2.64) | 0.006 | 0.153 |

Abbreviations: BMI, body mass index; IGF-1, insulin-like growth factor 1. *IGF-1 units are nmol l⁻¹. **BMI, height. ^Cancer, diabetes, cardiovascular disease. °Own wealth quintile per benefit unit (unit is a couple or single person along with their dependent children), education level. *Alcohol consumption, smoking, physical activity.

### Table 4. Odds ratio (95% confidence interval) for the longitudinal association between serum IGF-1 in 2008 and new depression symptoms in 2012: the English Longitudinal Study of Ageing

| IGF-1 quintile (range) | P-value for linearity | P-value for quadratic |
|------------------------|-----------------------|-----------------------|
| (2–11)                 | (12–14) | (15–16) | (17–20) | (21–65) |
| Women (analytical sample) | | | | |
| Adjustments | | | | |
| Age (2343) | 1 (ref) | 0.88 (0.60, 1.29) | 0.77 (0.51, 1.16) | 0.84 (0.53, 1.35) | 0.95 (0.60, 1.50) | 0.647 | 0.027 |
| Age, anthropometric measures (2276) | 1 | 0.84 (0.55, 1.35) | 0.76 (0.50, 1.16) | 0.84 (0.52, 1.36) | 0.93 (0.58, 1.48) | 0.652 | 0.033 |
| Age, co-morbidities (2342) | 1 | 0.86 (0.58, 1.26) | 0.77 (0.51, 1.16) | 0.84 (0.53, 1.35) | 0.94 (0.60, 1.49) | 0.649 | 0.014 |
| Age, psychosocial factors (2243) | 1 | 0.9 (0.60, 1.34) | 0.86 (0.56, 1.30) | 0.9 (0.55, 1.45) | 1.06 (0.66, 1.69) | 0.816 | 0.026 |
| Age, behavioural factors (2116) | 1 | 0.91 (0.61, 1.35) | 0.76 (0.49, 1.17) | 0.86 (0.52, 1.40) | 0.93 (0.58, 1.51) | 0.915 | 0.029 |
| Multiply adjusted (1969) | 1 | 0.86 (0.56, 1.31) | 0.78 (0.50, 1.23) | 0.87 (0.52, 1.46) | 0.94 (0.56, 1.57) | 0.922 | 0.008 |
| Men (analytical sample) | | | | |
| Adjustments | | | | |
| Age (2076) | 1 (ref) | 0.51 (0.28, 0.91) | 0.5 (0.27, 0.92) | 0.63 (0.35, 1.15) | 0.63 (0.35, 1.13) | 0.126 | 0.002 |
| Age, anthropometric measures (2042) | 1 | 0.51 (0.28, 0.94) | 0.5 (0.27, 0.93) | 0.66 (0.36, 1.20) | 0.63 (0.34, 1.14) | 0.142 | 0.002 |
| Age, co-morbidities (2070) | 1 | 0.52 (0.29, 0.92) | 0.56 (0.24, 0.85) | 0.64 (0.35, 1.16) | 0.65 (0.36, 1.16) | 0.098 | 0.002 |
| Age, psychosocial factors (2031) | 1 | 0.53 (0.29, 0.91) | 0.54 (0.29, 0.92) | 0.62 (0.33, 1.17) | 0.68 (0.37, 1.24) | 0.173 | 0.001 |
| Age, behavioural factors (2076) | 1 | 0.52 (0.27, 0.99) | 0.49 (0.25, 0.96) | 0.67 (0.35, 1.30) | 0.58 (0.30, 1.11) | 0.165 | 0.001 |
| Multiply adjusted (1765) | 1 | 0.51 (0.25, 1.02) | 0.5 (0.22, 0.95) | 0.67 (0.33, 1.33) | 0.6 (0.30, 1.19) | 0.072 | 0.003 |

Abbreviations: BMI, body mass index; IGF-1, insulin-like growth factor 1. *IGF-1 units are nmol l⁻¹. **BMI, height. ^Cancer, diabetes, cardiovascular disease. °Own wealth quintile per benefit unit (unit is a couple or single person along with their dependent children), education level. *Alcohol consumption, smoking, physical activity.
Strengthened limitations
The main strength of this study is that it has a large, nationally representative sample of people aged 50 years plus in whom there were high rates of follow-up when two standard measures of depression were administered. Our study is not of course without its limitations. The observational nature of our study indicates that we are not able to make any assertions about cause and effect. Although suggestions for mechanisms of action have been posited, it remains possible that IGF-1 levels are a proxy for other factors that are causally related to depression (residual confounding). Although our study was very well characterized, we are not able to control for all possible confounders. Furthermore, although the CES-D8 is a widely used questionnaire in observational studies, it does not provide a diagnosis of depression. Conversely, although self-reported physician-diagnosis of depression does, in principle, do this, many people with depression do not seek medical intervention. The use of anti-depressant medication, which also has some utility in identifying study members with a depression diagnosis, was not gathered in English Longitudinal Study of Ageing. It is also the case, however, that administration of such therapy does not necessarily imply a diagnosis of depression: anti-depressant medication can be used in the treatment of, among other conditions, anxiety and chronic pain disorders. The occurrence of missing data is inevitable in any large-scale study, and about 10% of participants had missing data for one or more of the covariates. However, sensitivity analysis comparing results across the cases with complete information and those with some missing covariates made little difference to outcomes, suggesting that major bias is unlikely. Finally, severe liver and kidney disease may influence IGF-1 levels, but we had no such data on these morbidities herein.

In conclusion, taken together, in the present study of older adults, having IGF-1 values at opposite ends of the continuum was associated with a somewhat increased risk of depression symptoms and physician-diagnosis of depression. Further studies are needed to examine whether the observed association is likely to be causal before meaningful discussions about normalizing IGF-1 levels with drugs could be useful in the prevention of depressive symptoms in older people.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

This work was supported by an ESRC-MRC studentship to SC. GDB is a member of The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative. Funding from the Biotechnology and Biological Sciences Research Council and Medical Research Council is acknowledged. MK is supported by the Medical Research Council (MR/ Biotechnology and Biological Sciences Research Council and Medical Research University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, This work was supported by an ESRC-MRC studentship to SC. GDB is a member of The Longitudinal Study of Ageing. It is also the case, however, that

REFERENCES

1. World Health Organization. Depression, Fact sheet No. 369, October 2012. Available at http://www.who.int/mediacentre/factsheets/fs369/en/ (accessed 23 January 2015).
2. World Health Organization. The Global Burden of Disease: 2004 Update. World Health Organization: Geneva, Switzerland, 2008.
3. Isometsa E, Henriksson M, Marttunen M, Heikkinen M, Aro H, Kuoppasalmi K et al. Mental disorders in young and middle aged men who commit suicide. BMJ 1995; 310: 1366–1367.
4. Bell S, Russ TC, Kivimäki M, Stamatakis E, Batty GD. Dose-response association between psychological distress and risk of completed suicide in the general population. JAMA Psychiatry 2015; 11: 1–3.
35 Jacobs BL, van Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 2000; 5: 262–269.

36 Torres Aleman I. Role of insulin-like growth factors in neuronal plasticity and neuroprotection. Adv Exp Med Biol 2005; 567: 243–258.

37 Sievers C, Auer MK, Klotsche J, Athanasoulia AP, Schneider HJ, Nauck M et al. IGF-I levels and depressive disorders: results from the Study of Health in Pomerania (SHIP). Eur Neuropsychopharmacol 2014; 24: 890–896.

38 van Varssseveld NC, van Bunderen, Sohl E, Cornis HC, Penninx BWJH, Lips P et al. Serum insulin-like growth factor 1 and late-life depression: a population-based study. Psychoneuroendocrinology 2015; 54: 31–40.

39 NatCen Social Research. English Longitudinal Study of Ageing (ELSA): Wave One to Wave Five—User Guide to the datasets. Available from http://www.ifs.org.uk/elsa/user_guides/waves_1_5_datasets_user_guide.pdf [accessed on 16 February 2015].

40 Freeman Laboratories Newcastle (2012). DPC Immulite 2000—IGF-I. (Laboratory summary of methods used up to 02 February 2012, available from laboratory on request).

41 Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385.

42 Steffick DE. Documentation of Affective Functioning Measures in the Health and Retirement Study. HRS Survey Research Center University of Michigan: Ann Arbor, MI, USA, 2000.

43 Karim J, Weisz R, Bibi Z, ur Rehman S. Validation of the eight-item Center for Affective Functioning Scale (CES-D) among older adults. Curr Psychol 2014; 1: 20.

44 Blake H, Mo P, Malik S, Thomas S. How effective are physical activity interventions for alleviating depressive symptoms in older people? A systematic review. Clin Rehabil 2009; 23: 873–887.

45 Reinecke MA, Schultz TM. Comparison of self-report and clinician ratings of depression among outpatient adolescents. Depression 1995; 3: 139–145.

46 Turvey CL, Wallace RB, Herzog R. A revised CES-D measure of depressive symptoms and a DSM-based measure of major depressive episodes in the elderly. Int Psychogeriatr 1999; 11: 139–148.

47 UK Data Archive Study Number 5050—English Longitudinal Study of Ageing (2009). English Longitudinal Study of Ageing Wave Four Interview Questionnaire —2008-2009 Draft Version 1.0. Available from http://www.ifs.org.uk/elsa/docs_w4/questionnaire_main.pdf [accessed on 3 May 2015].

48 Sanchez-Villegas A, Schlatter J, Ortuño F, Lahortiga F, Pla J, Bento S et al. Validity of a self-reported diagnosis of depression among participants in a cohort study using the Structured Clinical Interview for DSM-IV (SCID-I). BMC Psychiatry 2008; 8: 43.

49 Banks J, Breeze E, Crawford R, Demakakos P, de Oliveira C, Gjoenca E et al. Financial Circumstances, Health and Well-Being of the Older Population in England: The 2008 English Longitudinal Study of Ageing (wave 4). Institute of Fiscal Studies: London, UK, 2010.

50 Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women: the Rancho Bernardo Study. Am J Epidemiol 1997; 145: 970–976.

51 StataCorp LP. Stata 12 . StataCorp: College Station, TX, USA, 2011.

52 Sievers C, Dimopoulou C, Pfister H, Lieb R, Steffin B, Roemmler J et al. Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients. Clin Endocrinol (Oxf) 2009; 71: 691–701.

53 McGauley GA, Cuneo RC, Salomon F, Sonksen PH. Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. Horm Res 1990; 33(Suppl 4): 52–54.

54 Wexler T, Gunnell L, Omer Z, Kuhlthau K, Beauregard C, Graham G et al. Hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab 2009; 94: 2471–2477.

55 Deuschle M, Blum WF, Strasburger CJ, Schweiger U, Weber B, Korner A et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997; 22: 493–503.

56 Franz B, Buyssse DJ, Cherry CR, Gray NS, Grochocinski VJ, Frank E et al. Insulin-like growth factor I and growth hormone binding protein in depression: a preliminary study. J Psychiatr Res 1999; 33: 121–127.

I G F - 1 and risk of depression in older people
S Chigogora et al

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016

Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)